Andrew Sochacki, MD
Hematology & Oncology · Grand Rapids, MINPI 1003235391
Payments from drug & device makers
Across 380 payments — averaging $3623.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$392K
- Janssen Research & Development, LLC$351K
- Incyte Corporation$211K
- Boehringer Ingelheim$163K
- Bristol Myers Squibb$141K
- GSK$86K
- plus $33K from 23 others
Across 5 payments — averaging $66.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$227
- Servier Pharmaceuticals LLC$104
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 131 | $391,995 |
| Janssen Research & Development, LLC | 36 | $350,589 |
| Incyte Corporation | 105 | $211,184 |
| Boehringer Ingelheim | 30 | $163,376 |
| Bristol Myers Squibb | 13 | $140,841 |
| GSK | 7 | $86,010 |
| E.r. Squibb & Sons, L.L.C. | 7 | $24,567 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 2 | $7,487 |
| Pharmacyclics LLC, An Abbvie Company | 9 | $195 |
| Novartis | 5 | $94 |
| Johnson & Johnson | 3 | $92 |
| Genentech USA, Inc. | 4 | $85 |
| Sanofi | 3 | $79 |
| Gilead | 3 | $62 |
| Pfizer | 3 | $48 |
| Daiichi Sankyo Inc. | 2 | $46 |
| Beigene USA, Inc. | 2 | $45 |
| Amgen | 2 | $44 |
| AstraZeneca | 2 | $34 |
| Kyowa Kirin, Inc. | 2 | $33 |
| Tersera Therapeutics LLC | 1 | $31 |
| Merck | 1 | $31 |
| Springworks Therapeutics, Inc. | 1 | $20 |
| Genmab U.S., Inc. | 1 | $19 |
| Servier Pharmaceuticals LLC | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
| Acrotech Biopharma Inc. | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
How this compares
$1,377,086 in reported general payments places this provider in the 90th percentile of 282 hematology & oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Grand Rapids
- Sreenivasa ChandanaGrand Rapids$19.1M
- Nehal LakhaniGrand Rapids$15M
- Brett BrinkerGrand Rapids$2.3M
- Eric SantosGrand Rapids$1.5M
- Amy Vander WoudeGrand Rapids$1.2M
- Colin HardinGrand Rapids$974K
- Erin PettijohnGrand Rapids$871K
- Latha PolavaramGrand Rapids$69K
- Timothy OrourkeGrand Rapids$55K
- Hirva MamdaniDetroit$9.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.